Results 151 to 160 of about 1,071,501 (260)

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants. [PDF]

open access: yesHepatol Commun, 2023
Thompson AJ   +27 more
europepmc   +1 more source

A comparative viral load evaluation for human immunodeficiency virus, hepatitis B virus and hepatitis C virus of the Roche cobas 5800, Abbott Alinity m and Hologic Panther

open access: yesVox Sanguinis, EarlyView.
Abstract Background and Objectives Viral load (VL) quantification for human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) is essential for clinical monitoring, treatment response assessment and post‐donation interpretation.
Adriaan Meyer, Suné Saayman
wiley   +1 more source

HIV Testing and Care Among Publicly Insured Enrollees With Schizophrenia: Is There a Benefit to Dual Eligibility?

open access: yesPsychiatric Research and Clinical Practice, EarlyView.
Background Patients with schizophrenia experience gaps in the human immunodeficiency virus (HIV) care continuum. We examined the impact of dual enrollment in Medicare upon HIV testing and retention among Medicaid‐enrolled patients with schizophrenia.
Karly Murphy   +13 more
wiley   +1 more source

Sequencing of serum hepatitis B virus (HBV) RNA as a novel method for the genome analysis of HBV

open access: yes, 2016
The genome of hepatitis B virus (HBV) can be assessed by sequence analysis of HBV DNA in serum. In most chronic HBV infected patients treated with potent nucleos(t)ide analogues (NAs) this approach however is limited by the fast decrease of serum HBV DNA during NA treatment.
openaire   +2 more sources

ANP32A and ANP32B bridge HBV RNA-ELAVL1-CRM1 and mediate HBV RNAs nuclear export.

open access: yes
(A-D) HepG2-NTCP cells were transfected with ANP32A or ANP32B targeted siRNA. The cells were infected with HBV at an MOI = 200 and were maintained with DMEM medium supplemented with 2.5% DMSO for 5 days.
Chuanjian Wu (15877596)   +16 more
core   +1 more source

Non–AIDS‐Defining Cancer Incidence in People With HIV in Milan, Italy, 2000–2023: Temporal Trends and Comparison With the General Population

open access: yesInternational Journal of Cancer, Volume 159, Issue 12, Page 2870-2876, 15 December 2026.
ABSTRACT People with HIV (PWH) are living longer, but contemporary data on non–AIDS‐defining cancers (NADCs) in Italy remain limited. We assessed incident cancers in a retrospective cohort of PWH in Milan, Italy, between January 2000 and December 2023. Follow‐up was grouped into 2000–2007, 2008–2015, and 2016–2023. Incidence rates (IRs) were calculated
Giacomo Pozza   +14 more
wiley   +1 more source

Stem cell‐based platforms for cancer therapy: Biological mechanisms, therapeutic applications and clinical translation

open access: yesClinical and Translational Discovery, Volume 6, Issue 6, December 2026.
Stem cell platforms offer distinct therapeutic, supportive and research‐enabling applications in oncology. Haematopoietic stem cell transplantation is established for selected haematological malignancies. Engineered MSCs, NSCs and pluripotent stem cell‐derived products remain investigational anticancer platforms.
Ruba Altahla   +5 more
wiley   +1 more source

Dynamic Changes in Metabolic Syndrome and Risk of Hepatocellular Carcinoma: Evidence From a Nationwide Japanese Cohort

open access: yesLiver International Communications, Volume 7, Issue 4, December 2026.
ABSTRACT Aim Metabolic syndrome (MetS) is a known risk factor for hepatocellular carcinoma (HCC), but the impact of cumulative MetS burden and changes in MetS status over time remains unclear. This study aimed to assess these associations using a large‐scale Japanese health dataset.
Yutaka Yata   +9 more
wiley   +1 more source

Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy